SimonMed offers quantification of brain structures, using FDA cleared software which references a known “healthy” database, and can provide physicians with an early indication of Alzheimer’s disease for those with mild cognitive impairment. The software can also be used by physicians to monitor progression, and characterize more severe findings, as well focal white matter disease.

Using high resolution scanning, SimonMed can quantify volumes of multiple structures, including the hippocampus. Patients with a smaller than normal hippocampus (for their age and gender) are much more likely to progress to Alzheimer’s disease.

SimonMed, unlike many specialized centers, does not charge extra for this added quantification which can be both costly and time consuming.

NeuroQuant compares a MRI of a patient’s brain to a normative reference database, cleared by the U.S. Food and Drug Administration, of people of the same age, gender and intracranial volume who have healthy brains. NeuroQuant can provide physicians with an early warning of Alzheimer’s disease for patients who have mild cognitive impairment. Research has shown a correlation between the size of the hippocampus and the onset of Alzheimer’s disease. Patients who have a smaller than normal hippocampus (for their age and gender) are four times more likely to progress to Alzheimer’s disease in a few years than patients whose hippocampus is a normal size (for their age and gender). The hippocampus in a healthy patient shrinks about 1 percent per year compared to about 5 percent per year in a person with Alzheimer’s disease.

NeuroQuant can aid physicians in monitoring changes in brain volumes over time to determine if there is atrophy and how quickly a disease is progressing.